FibroGen (FGEN) Highlights Results from Ph. 3 HIMALAYAS Trial Evaluating Roxadustat for Treatment of Anemia in Incident Dialysis Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to FibroGen (FGEN) Highlights Results from Ph. 3 HIMALAYAS Trial Evaluating Roxadustat for Treatment of Anemia in Incident Dialysis Patients

FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease

November 7, 2019 4:39 PM EST

WASHINGTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced results from the Phase 3 HIMALAYAS trial evaluating roxadustat for the treatment of anemia in incident dialysis (ID) patients with chronic kidney disease (CKD), a clinically important subgroup of dialysis-dependent CKD patients.  Incident dialysis was defined as those who initiated dialysis within 4 months before randomization to roxadustat or epoetin alfa. In this trial of 1,043 patients, believed to be the largest trial to date investigating an anemia medicine in the ID population, roxadustat achieved both primary efficacy endpoints. The safety profile of roxadustat observed in... More